ADC Therapeutics cuts 17% of staff after 27 patient deaths in Zynlonta trial on June 25, 2026 Diffuse Large B-Cell Lymphoma Grade five rank layoffs LOTIS-5 Overall Survival patient deaths Progression-Free Survival reorganization TEAEs therapeutic autologous dendritic cells workforce reduction Zynlonta +
Valneva to cut up to 15% of jobs as reduced travel hits vaccine demand on May 14, 2026 Dukoral geopolitical factors guidance cut Ixchiq Ixiaro layoffs Lyme Disease operating costs restructuring travel Vaccines Valneva VLA15 workforce reduction +
Replimune Lays Off 60% of Workforce After Second FDA Rejection of RP1 Melanoma Drug on April 21, 2026 layoffs melanoma rejection Replimune RETINITIS PIGMENTOSA 1 United States Food and Drug Administration workforce reduction +
Theravance Biopharma Halves Workforce and Ends R&D After Phase 3 Failure on March 04, 2026 ampreloxetine CYPRESS study Phase 3 failure R&D shutdown Theravance Biopharma workforce reduction Yupelri +
Nxera Pharma to Cut 15% of Workforce in Japan and UK as Part of Restructuring Plan on November 19, 2025 GPCR pipeline Japan Nxera Pharma optimization Organization administrative structures profitability restructuring Surgical aspects UK workforce reduction +